Abstract
Carbamazepine (CBZ) is the antiepileptic drug of choice for partial and tonic-clonic seizure. CBZ is metabolized by the cytochrome P450 (CYP) system, particularly the isoforms CYP3A4 and CYP3A5. A number of allelic variants have been described for CYP3A4 and CYP3A5 potentially affecting the expression/activity of the enzymes with influences on drug metabolism. In order to evaluate the impact of CYP3A polymorphisms on CBZ plasma levels, 29 epileptic patients in CBZ therapy at steady-state were genotyped for CYP3A4 (*1B, *3, *4) e and CYP3A5 (*2,*3,*6) and the CBZ plasma levels measured.
Titolo tradotto del contributo | Impact of CYP3A polymorphism on carbamazepine plasmatic levels |
---|---|
Lingua originale | Italian |
pagine (da-a) | 205-207 |
Numero di pagine | 3 |
Rivista | Bollettino - Lega Italiana contro l'Epilessia |
Numero di pubblicazione | 140 |
Stato di pubblicazione | Pubblicato - apr 2010 |
Keywords
- CYP3A
- Carbamazepine
- Plasma levels
- Polymorphism